Table 1 Baseline characteristics of the study population
Normal eGFR at baseline | Low eGFR at baseline | |
|---|---|---|
(⩾60 ml min−1 per 1.73 m2) | (<60 ml min−1 per 1.73 m2) | |
n=1015 | n=520 | |
Age, year | 65.7±10.7 | 71.1±9.4 |
Men, % | 46.8 | 43.9 |
Body mass index, kg m−2 | 24.1±3.4 | 24.1±3.2 |
Current smoker, % | 10.1 | 11.2 |
Current drinker, % | 25.3 | 24.6 |
Family history of hypertension, % | 42.3 | 47.5 |
Complications | ||
History of stroke, % | 7.4 | 9.8 |
History of ischemic heart disease, % | 6.2 | 12.5 |
Diabetes, % | 15.9 | 21.4 |
Dyslipidemia, % | 51.2 | 55.4 |
High uric acid, % | 15.3 | 29.2 |
Baseline eGFR, ml min−1 per 1.73 m2 | 75.9±12.9 | 49.1±8.1 |
Follow-up eGFR, ml min−1 per 1.73 m2 | 74.8±14.3 | 47.1±8.0 |
ΔeGFR, ml min−1 per 1.73 m2 per year | -0.6±9.2 | 5.2±8.8 |
Treat period ⩾1 year, % | 51.0 | 59.2 |
Number of drugs ⩾3, % | 24.3 | 39.2 |
Class of drug, % | ||
Ca channel blockers | 73.1 | 79.2 |
ARBs | 56.2 | 58.1 |
ACE inhibitors | 13.6 | 15.4 |
Diuretics | 14.3 | 22.5 |
β-blockers | 13.4 | 21.5 |
α-blockers | 16.0 | 15.8 |
αβ-blockers | 6.0 | 7.9 |
